Clinical Trials Logo

Clinical Trial Summary

Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (>18 years) with house dust mite allergy over a period of 12 months.


Clinical Trial Description

Condition: - persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving medication - HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03746860
Study type Observational
Source ALK-Abelló A/S
Contact
Status Completed
Phase
Start date May 9, 2018
Completion date September 29, 2020

See also
  Status Clinical Trial Phase
Completed NCT04145219 - House Dust Mite Allergy Trial In Children Phase 3
Not yet recruiting NCT05510024 - Radiofrequency Ablation of Bilateral Inferior Turbinate Followed by Subcutaneous Immunotherapy Trial N/A
Enrolling by invitation NCT06151938 - Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
Enrolling by invitation NCT05960526 - Nasal Irrigation With Combination of 0.9% NaCl and Binahong Extract (Anredera Cordifolia) 2,5% In Allergic Rhinitis Phase 1
Active, not recruiting NCT04286542 - Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis N/A
Completed NCT03654976 - Mite Asthma Pediatric Immunotherapy Trial Phase 3